| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
50.94
|
|
2
|
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
41.47
|
|
3
|
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
26.95
|
|
4
|
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.
|
JAMA
|
2013
|
10.43
|
|
5
|
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
|
Lancet
|
2015
|
7.99
|
|
6
|
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.
|
Lancet
|
2015
|
6.13
|
|
7
|
Burden of disease and cost of chronic hepatitis C infection in Canada.
|
Can J Gastroenterol Hepatol
|
2014
|
1.59
|
|
8
|
Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas.
|
J Med Econ
|
2012
|
1.19
|
|
9
|
Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
|
J Gastroenterol Hepatol
|
2014
|
1.02
|
|
10
|
Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
|
N Z Med J
|
2014
|
0.84
|
|
11
|
The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
|
Scand J Gastroenterol
|
2014
|
0.79
|
|
12
|
Interferon-based hepatitis C antiviral treatment outcomes may be predicted by alanine aminotransferase levels.
|
Can J Gastroenterol Hepatol
|
2015
|
0.75
|
|
13
|
Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
|
MMWR Morb Mortal Wkly Rep
|
2020
|
0.75
|